Key result
Laropiprant prevents niacin-mediated flush more effectively than aspirin or NSAIDs.
Why the study?
Niacin therapy is used to treat dyslipidemia but is associated with flushing, and effective prevention strategies for this side effect require further clarification.
Answers are grounded in this paper and cite their sources.
Flush control may enhance niacin tolerability in dyslipidemia; leaves open its role versus contemporary therapies.
There are many factors that increase the risk of cardiovascular disease, and a prominent factor among these is dyslipidemia. The following literature review focuses on the use of niacin therapy in order to treat dyslipidemia and how to control the associated "niacin flush." The associated studies gathered are reviews and randomized control trials. They were obtained by using electronic searches. Certain keywords took precedence, and articles focusing on niacin therapy were chosen. Recent research has found promising insight into more effective prevention of the niacin-mediated flush through a selective antagonist for the prostaglandin D2 receptor, laropiprant. Aspirin (or NSAIDs) also provide some prevention for flushing, although recent studies have shown that it is not as effective as laropiprant. There is a need for further research in order to come to a clear conclusion regarding combined therapies of aspirin and laropiprant pretreatment, as well as exact dosage requirements.
No takes yet. Share an insight, caveat, or question.
Sood et al. (2009) conducted a review in Dyslipidemia and niacin flush. Niacin therapy and flush prevention (laropiprant, aspirin/NSAIDs) was evaluated. Laropiprant, a selective prostaglandin D2 receptor antagonist, provides more effective prevention of niacin-mediated flush than aspirin or NSAIDs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: